GH Research (NASDAQ:GHRS) Trading 8.5% Higher - Still a Buy?

GH Research PLC (NASDAQ:GHRS - Get Free Report) was up 8.5% during trading on Monday . The company traded as high as $19.00 and last traded at $19.07. Approximately 211,830 shares traded hands during trading, an increase of 5% from the average daily volume of 202,304 shares. The stock had previously closed at $17.57.

Analyst Upgrades and Downgrades

Several analysts recently commented on GHRS shares. Guggenheim decreased their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald began coverage on GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 target price on the stock. Wall Street Zen raised GH Research from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of GH Research in a research note on Friday, May 9th. Finally, JMP Securities restated a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research report on Tuesday, June 24th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

GH Research Trading Up 11.0%

The business has a fifty day moving average price of $12.99 and a 200 day moving average price of $11.50.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.42. Research analysts predict that GH Research PLC will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in GH Research during the 4th quarter worth $44,000. Two Sigma Investments LP bought a new stake in GH Research during the fourth quarter worth about $117,000. Palumbo Wealth Management LLC bought a new stake in GH Research during the first quarter worth about $142,000. Millennium Management LLC acquired a new stake in shares of GH Research in the fourth quarter valued at $145,000. Finally, XTX Topco Ltd acquired a new stake in shares of GH Research in the first quarter valued at approximately $169,000. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.